Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management

References

• Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v69–v77.
   PubMedGoogle Scholar
• Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106.
   PubMed Web of Science ®Google Scholar
• Brawer MK. Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer. Rev Urol. 2004;6(Suppl 8):S3–S9.
   PubMedGoogle Scholar
• Aragon-Ching JB, Dahut WL. Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. Drug Discov Today Ther Strateg. 2010;7(1–2):31–35.
   PubMedGoogle Scholar
• Rhee H, Gunter JH, Heathcote P, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115(Suppl 5):3–13.
   PubMed Web of Science ®Google Scholar
• Sountoulides P, Rountos T. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol. 2013;2013:240108.
   PubMedGoogle Scholar
• Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388–2399.
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396.
   PubMed Web of Science ®Google Scholar
• Salminen EK, Portin RI, Koskinen A, et al. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004;10(22):7575–7582.
   PubMed Web of Science ®Google Scholar
• Gonzalez BD, Jim HS, Booth-Jones M, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–2027.
   PubMed Web of Science ®Google Scholar
• Edmunds K, Tuffaha H, Galvao DA, et al. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer. 2020;28(5):2079–2093.
   PubMed Web of Science ®Google Scholar
• Patil T, Bernard B. Complications of androgen deprivation therapy in men with prostate cancer. Oncology. 2018;32(9):470–474.
   PubMed Web of Science ®Google Scholar
• DiBlasio CJ, Hammett J, Malcolm JB, et al. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol. 2008;15(5):4249–4256.
   PubMed Web of Science ®Google Scholar
• Pirl WF, Siegel GI, Goode MJ, et al. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002;11(6):518–523.
   PubMed Web of Science ®Google Scholar
• Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology. 2009;18(3):237–247.
   PubMed Web of Science ®Google Scholar
• Soyupek F, Soyupek S, Perk H, et al. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol. 2008;26(2):141–146.
   PubMed Web of Science ®Google Scholar
• Ng HS, Koczwara B, Roder D, et al. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis. 2018;21(3):403–410.
   PubMed Web of Science ®Google Scholar
• Downing A, Wright P, Hounsome L, et al. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncol. 2019;20(3):436–447.
   PubMed Web of Science ®Google Scholar
• Seidman SN, Walsh BT. Testosterone and depression in aging men. Am J Geriatr Psychiatry. 1999;7(1):18–33.
   PubMed Web of Science ®Google Scholar
• Carnahan RM, Perry PJ. Depression in aging men: the role of testosterone. Drugs Aging. 2004;21(6):361–376.
   PubMed Web of Science ®Google Scholar
• Shores MM, Moceri VM, Sloan KL, et al. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry. 2005;66(01):7–14.
   PubMedGoogle Scholar
• Amore M, Innamorati M, Costi S, et al. Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol. 2012;2012:280724.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab. 1999;84(2):573–577.
   PubMed Web of Science ®Google Scholar
• Seidman SN, Araujo AB, Roose SP, et al. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry. 2001;50(5):371–376.
   PubMed Web of Science ®Google Scholar
• Rohr UD. The impact of testosterone imbalance on depression and women's health. Maturitas. 2002;41(Suppl 1):S25–S46.
   PubMedGoogle Scholar
• Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015;1(6):CD011006.
   Google Scholar
• Ng CG, Boks MP, Zainal NZ, et al. The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord. 2011;131(1–3):1–7.
   PubMed Web of Science ®Google Scholar
• Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15(2):123–136.
   PubMed Web of Science ®Google Scholar
• Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94(3):372–390.
   PubMed Web of Science ®Google Scholar
• Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc. 2010;303(1):47–53.
   PubMed Web of Science ®Google Scholar
• Laoutidis ZG, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140.
   PubMed Web of Science ®Google Scholar
• Caruso R, GiuliaNanni M, Riba MB, et al. Depressive spectrum disorders in cancer: diagnostic issues and intervention. A critical review. Curr Psychiatry Rep. 2017;19(6):33.
   PubMed Web of Science ®Google Scholar
• Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;2004(32):57–71.
   Google Scholar
• Smith HR. Depression in cancer patients: pathogenesis, implications and treatment (review). Oncol Lett. 2015;9(4):1509–1514.
   PubMed Web of Science ®Google Scholar
• Niedzwiedz CL, Knifton L, Robb KA, et al. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer. 2019;19(1):943.
   PubMed Web of Science ®Google Scholar
• Walker J, Holm Hansen C, Martin P, et al. Prevalence of depression in adults with cancer: a systematic review. Ann Oncol. 2013;24(4):895–900.
   PubMed Web of Science ®Google Scholar
• Jayadevappa R, Malkowicz SB, Chhatre S, et al. The burden of depression in prostate cancer. Psychooncology. 2012;21(12):1338–1345.
   PubMed Web of Science ®Google Scholar
• Prasad SM, Eggener SE, Lipsitz SR, et al. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014;32(23):2471–2478.
   PubMed Web of Science ®Google Scholar
• Amiri S, Behnezhad S. Cancer diagnosis and suicide mortality: a systematic review and meta-analysis. Arch Suicide Res. 2020;24(sup2):S94–S112.
   PubMedGoogle Scholar
• Schneider S, Moyer A. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2010;116(13):3304. Author reply 3305.
   PubMed Web of Science ®Google Scholar
• Giese-Davis J, Collie K, Rancourt KM, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29(4):413–420.
   PubMed Web of Science ®Google Scholar
• Grassi L, Nanni MG, Caruso R. Emotional distress in cancer: screening policy, clinical limitations and educational needs. J Med Pers. 2010;8(2):51–59.
   Google Scholar
• Pitman A, Suleman S, Hyde N, et al. Depression and anxiety in patients with cancer. BMJ. 2018;361:k1415.
   PubMed Web of Science ®Google Scholar
• Dauchy S, Dolbeault S, Reich M. Depression in cancer patients. EJC Suppl. 2013;11(2):205–215.
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807–1823.
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11.
   PubMedGoogle Scholar
• Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol. 2009;5:363–389.
   PubMed Web of Science ®Google Scholar
• Gray RE, Fitch M, Phillips C, et al. To tell or not to tell: patterns of disclosure among men with prostate cancer. Psychooncology. 2000;9(4):273–282.
   PubMed Web of Science ®Google Scholar
• Erim DO, Bensen JT, Mohler JL, et al. Prevalence and predictors of probable depression in prostate cancer survivors. Cancer. 2019;125(19):3418–3427.
   PubMed Web of Science ®Google Scholar
• NIH. Transforming and understanding and treatment of mental illnesses, men and depression 2017. [cited 2021]. Available from: https://www.nimh.nih.gov/health/publications/men-and-depression/.
   Google Scholar
• Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4(3):e003901.
   PubMed Web of Science ®Google Scholar
• Lintz K, Moynihan C, Steginga S, et al. Prostate cancer patients' support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology. 2003;12(8):769–783.
   PubMed Web of Science ®Google Scholar
• Rice SM, Oliffe JL, Kelly MT, et al. Depression and prostate cancer: examining comorbidity and male-specific symptoms. Am J Mens Health. 2018;12(6):1864–1872.
   PubMed Web of Science ®Google Scholar
• Handa R, McGivern R. Androgen receptors in the brain: a behavioral perspective. In: Chang CC, editor. Androgens and androgen receptor: mechanisms, functions and clinical applications. New York (NY): Kluwer Academic/Plenum Publishers; 2002.
   Google Scholar
• Hofer P, Lanzenberger R, Kasper S. Testosterone in the brain: neuroimaging findings and the potential role for neuropsychopharmacology. Eur Neuropsychopharmacol. 2013;23(2):79–88.
   PubMed Web of Science ®Google Scholar
• Pandya M, Altinay M, Malone DA, Jr, et al. Where in the brain is depression? Curr Psychiatry Rep. 2012;14(6):634–642.
   PubMed Web of Science ®Google Scholar
• McHenry J, Carrier N, Hull E, et al. Sex differences in anxiety and depression: role of testosterone. Front Neuroendocrinol. 2014;35(1):42–57.
   PubMed Web of Science ®Google Scholar
• Lima-Ojeda JM, Rupprecht R, Baghai TC. Neurobiology of depression: a neurodevelopmental approach. World J Biol Psychiatry. 2018;19(5):349–359.
   PubMed Web of Science ®Google Scholar
• Hammond GL, Hirvonen J, Vihko R. Progesterone, androstenedione, testosterone, 5 alpha-dihydrotestosterone and androsterone concentrations in specific regions of the human brain. J Steroid Biochem. 1983;18(2):185–189.
   PubMedGoogle Scholar
• Lanthier A, Patwardhan VV. Sex steroids and 5-en-3 beta-hydroxysteroids in specific regions of the human brain and cranial nerves. J Steroid Biochem. 1986;25(3):445–449.
   PubMedGoogle Scholar
• Schweiger U, Deuschle M, Weber B, et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med. 1999;61(3):292–296.
   PubMed Web of Science ®Google Scholar
• O'Connor DB, Archer J, Hair WM, et al. Activational effects of testosterone on cognitive function in men. Neuropsychologia. 2001;39(13):1385–1394.
   PubMed Web of Science ®Google Scholar
• Shores MM, Sloan KL, Matsumoto AM, et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61(2):162–167.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini D, Eisfeld BS, et al. Calculated bioavailable testosterone levels and depression in middle-aged men. Psychoneuroendocrinology. 2006;31(9):1029–1035.
   PubMed Web of Science ®Google Scholar
• Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men–a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3578–3583.
   PubMed Web of Science ®Google Scholar
• Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18(1):20–24.
   PubMed Web of Science ®Google Scholar
• Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80–88.
   PubMed Web of Science ®Google Scholar
• Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289–305.
   PubMed Web of Science ®Google Scholar
• Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48(2–3):157–161.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–624.
   PubMed Web of Science ®Google Scholar
• Fink G, Sumner B, Rosie R, et al. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res. 1999;105(1):53–68.
   PubMed Web of Science ®Google Scholar
• Bethea CL, Coleman K, Phu K, et al. Relationships between androgens, serotonin gene expression and innervation in male macaques. Neuroscience. 2014;274:341–356.
   PubMed Web of Science ®Google Scholar
• Kranz GS, Wadsak W, Kaufmann U, et al. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biol Psychiatry. 2015;78(8):525–533.
   PubMed Web of Science ®Google Scholar
• Salminen E, Portin R, Korpela J, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer. 2003;89(6):971–976.
   PubMed Web of Science ®Google Scholar
• Pirl WF, Greer JA, Goode M, et al. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology. 2008;17(2):148–153.
   PubMed Web of Science ®Google Scholar
• Timilshina N, Breunis H, Alibhai S. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer. Cancer. 2012;118(7):1940–1945.
   PubMed Web of Science ®Google Scholar
• Wiechno PJ, Sadowska M, Kalinowski T, et al. Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?. Psychooncology. 2013;22(2):346–351.
   PubMed Web of Science ®Google Scholar
• Hervouet S, Savard J, Ivers H, et al. Depression and androgen deprivation therapy for prostate cancer: a prospective controlled study. Health Psychol. 2013;32(6):675–684.
   PubMed Web of Science ®Google Scholar
• Houede N, Rebillard X, Bouvet S, et al. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer. 2020;20(1):757.
   PubMed Web of Science ®Google Scholar
• Alonso-Quinones H, Stish BJ, Aakre JA, et al. Androgen deprivation therapy use and risk of mild cognitive impairment in prostate cancer patients. Alzheimer Dis Assoc Disord. 2021;35(1):44–47.
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez V, Buigues C, Navarro-Martinez R, et al. Analysis of brain functions in men with prostate cancer under androgen deprivation therapy: a one-year longitudinal study. Life. 2021;11(3):227.
   PubMedGoogle Scholar
• Cinar O, Turunc T, Kazaz IO, et al. Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: a multicentric, prospective study of the society of urological surgery andrology group. Int J Clin Pract. 2021;75(6):e14095.
   PubMed Web of Science ®Google Scholar
• Rosenblatt DE, Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract. 1995;8(4):317–320.
   PubMedGoogle Scholar
• Brawer MK. Testosterone replacement therapy for a man with prostate cancer. Rev Urol. 2004;6(Suppl 6):S35–S37.
   PubMedGoogle Scholar
• Shahinian VB, Kuo YF, Freeman JL, et al. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166(4):465–471.
   PubMedGoogle Scholar
• Kohen I, Koppel J. Goserelin-induced new-onset depressive disorder. Psychosomatics. 2006;47(4):360–361.
   PubMed Web of Science ®Google Scholar
• van Tol-Geerdink JJ, Leer JW, van Lin EN, et al. Depression related to (neo) adjuvant hormonal therapy for prostate cancer. Radiother Oncol. 2011;98(2):203–206.
   PubMed Web of Science ®Google Scholar
• Saini A, Berruti A, Cracco C, et al. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. Urol Oncol. 2013;31(3):352–358.
   PubMed Web of Science ®Google Scholar
• Sharpley CF, Christie DR, Bitsika V. Do hormone treatments for prostate cancer cause anxiety and depression?. Int J Clin Oncol. 2014;19(3):523–530.
   PubMed Web of Science ®Google Scholar
• Sharpley CF, Bitsika V, Wootten AC, et al. Differences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are not. Psychooncology. 2014;23(12):1350–1355.
   PubMed Web of Science ®Google Scholar
• Ahmadi-Davis S, Velasco R, Stewart JT. Goserelin-induced depression in a man with prostate cancer. Psychosomatics. 2014;55(6):720–722.
   PubMed Web of Science ®Google Scholar
• Lee M, Jim HS, Fishman M, et al. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology. 2015;24(4):472–477.
   PubMed Web of Science ®Google Scholar
• Kao LC, Chen LF, Hsu YC, et al. Escitalopram in treatment of antiandrogen-related mood disturbance in a patient with chronic schizophrenia and adenocarcinoma of the prostate. Gen Hosp Psychiatry. 2015;37(4):e11–e12.
   PubMed Web of Science ®Google Scholar
• Dinh KT, Reznor G, Muralidhar V, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34(16):1905–1912.
   PubMed Web of Science ®Google Scholar
• Chung SD, Kao LT, Lin HC, et al. Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder. PLOS One. 2017;12(3):e0173266.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang L, Xie D, et al. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: a 15-month prospective, observational study. Psychooncology. 2017;26(12):2238–2244.
   PubMed Web of Science ®Google Scholar
• Gagliano-Juca T, Travison TG, Nguyen PL, et al. Effects of androgen deprivation therapy on pain perception, quality of life, and depression in men with prostate cancer. J Pain Symptom Manage. 2018;55(2):307–317.
   PubMed Web of Science ®Google Scholar
• Thomas HR, Chen MH, D'Amico AV, et al. Association between androgen deprivation therapy and patient-reported depression in men with recurrent prostate cancer. Clin Genitourin Cancer. 2018;16(4):313–317.
   PubMed Web of Science ®Google Scholar
• Ceylan Y, Gunlusoy B, Koskderelioglu A, et al. The depressive effects of androgen deprivation therapy in locally advanced or metastatic prostate cancer: a comparative study. Aging Male. 2020;23(5):733–739.
   PubMed Web of Science ®Google Scholar
• Deka R, Rose BS, Bryant AK, et al. Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. Cancer. 2019;125(7):1070–1080.
   PubMed Web of Science ®Google Scholar
• Tully KH, Nguyen DD, Herzog P, et al. Risk of dementia and depression in young and middle-aged men presenting with nonmetastatic prostate cancer treated with androgen deprivation therapy. Eur Urol Oncol. 2021;4(1):66–72.
   PubMed Web of Science ®Google Scholar
• Shin D, Shim SR, Kim CH. Changes in beck depression inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy. PLOS One. 2020;15(6):e0234264.
   PubMed Web of Science ®Google Scholar
• Holtfrerich SKC, Knipper S, Purwins J, et al. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients. Psychooncology. 2020;29(8):1338–1346.
   PubMed Web of Science ®Google Scholar
• Chen YZ, Chiang PK, Lin WR, et al. The relationship between androgen deprivation therapy and depression symptoms in patients with prostate cancer. Aging Male. 2020;23(5):629–634.
   PubMed Web of Science ®Google Scholar
• Hoogland AI, Jim HSL, Gonzalez BD, et al. Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: preliminary findings. Cancer. 2021;127(9):1476–1482.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998;16(7):2377–2381.
   PubMed Web of Science ®Google Scholar
• Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999;162(1):98–102.
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Kanazawa S, Watanabe R, et al. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004;11(9):735–741.
   PubMed Web of Science ®Google Scholar
• Naoe M, Ogawa Y, Shichijo T, et al. Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(3):275–278.
   PubMed Web of Science ®Google Scholar
• Vitolins MZ, Griffin L, Tomlinson WV, et al. Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol. 2013;31(32):4092–4098.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Abello A, Bubley G. Testosterone therapy in men with biochemical recurrence and metastatic prostate cancer: initial observations. Androg Clin Res Ther. 2021;2(1):121–128.
   Google Scholar